ESMO 2022 | EV-103 Cohort K: enfortumab vedotin +/- pembro in untreated cis-ineligible patients with mUC

Tolerable first-line treatment options in metastatic urothelial carcinoma (mUC) represent an unmet clinical need. In this interview, Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the results of Cohort K of the EV-103 study (NCT03288545) which aimed to evaluate the antitumor activity of enfortumab vedotin monotherapy or in combination with pembrolizumab in previously untreated cisplatin-ineligible patients with locally advanced or mUC. Enfortumab vedotin plus pembrolizumab showed high overall response rates with rapid responses. Median duration of response was not reached in this patient population. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.